Prognostic value and immune landscapes of cuproptosis-related lncRNAs in esophageal squamous cell carcinoma
CONCLUSIONS: The above risk score and nomogram can accurately predict prognosis in ESCC patients and provide guidance for chemotherapy and immunotherapy.PMID:37812189 | DOI:10.18632/aging.205089 (Source: Aging)
Source: Aging - October 9, 2023 Category: Biomedical Science Authors: Xiang Zhang Nan Feng Bo Wu Zishun Guo Tiewen Pan Xiandong Tao Hongyang Zheng Wenxiong Zhang Source Type: research
Prognostic value and immune landscapes of cuproptosis-related lncRNAs in esophageal squamous cell carcinoma
CONCLUSIONS: The above risk score and nomogram can accurately predict prognosis in ESCC patients and provide guidance for chemotherapy and immunotherapy.PMID:37812189 | DOI:10.18632/aging.205089 (Source: Aging)
Source: Aging - October 9, 2023 Category: Biomedical Science Authors: Xiang Zhang Nan Feng Bo Wu Zishun Guo Tiewen Pan Xiandong Tao Hongyang Zheng Wenxiong Zhang Source Type: research
Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis
CONCLUSION: Eleven trials involving 4502 patients were analyzed in this study. Patients treated with second-generation TKIs were significantly more likely to experience cutaneous adverse events than those treated with imatinib with a relative risk (RR) of 1.62 (95% confidence interval [CI], [1.25-2.09]). Except dasatinib (RR [95% CI], 1.39 [0.75-2.56]), the risk of adverse events was more with second-generation TKIs than with imatinib as follows: nilotinib (2.11 [1.53-2.90]), bosutinib (1.41 [1.07-1.86]), and radotinib (1.87 [1.33-2.63]). Rash was the most common cutaneous adverse event that was observed in 21.6% of cases ...
Source: Acta Oncologica - October 3, 2023 Category: Cancer & Oncology Authors: Seung-Hyeon Cha Kyungim Kim Yun-Kyoung Song Source Type: research
Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis
CONCLUSION: Eleven trials involving 4502 patients were analyzed in this study. Patients treated with second-generation TKIs were significantly more likely to experience cutaneous adverse events than those treated with imatinib with a relative risk (RR) of 1.62 (95% confidence interval [CI], [1.25-2.09]). Except dasatinib (RR [95% CI], 1.39 [0.75-2.56]), the risk of adverse events was more with second-generation TKIs than with imatinib as follows: nilotinib (2.11 [1.53-2.90]), bosutinib (1.41 [1.07-1.86]), and radotinib (1.87 [1.33-2.63]). Rash was the most common cutaneous adverse event that was observed in 21.6% of cases ...
Source: Acta Oncologica - October 3, 2023 Category: Cancer & Oncology Authors: Seung-Hyeon Cha Kyungim Kim Yun-Kyoung Song Source Type: research
The Long-term Efficacy and Safety of Nilotinib in Pediatric Patients With CML: a 5-Year Update of the DIALOG Study
Blood Adv. 2023 Sep 22:bloodadvances.2023010122. doi: 10.1182/bloodadvances.2023010122. Online ahead of print.ABSTRACTThe efficacy and safety of nilotinib in pediatric patients with imatinib/dasatinib resistant/intolerant (R/I) or newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) was demonstrated in the phase II, open-label DIALOG study. In this final analysis, long-term efficacy and safety are presented for patients who completed 66 cycles (of 28 days) of treatment with nilotinib (230 mg/m2 twice daily) or discontinued early. Fifty-nine patients were enrolled an...
Source: Adv Data - September 22, 2023 Category: Epidemiology Authors: Nobuko Hijiya Alexey Maschan Carmelo Rizzari Hiroyuki Shimada Carlo Dufour Hiroaki Goto Hyoung Jin Kang Terri Guinipero Zeynep Karakas Francisco Bautista St éphane Ducassou Keon Hee Yoo Christian Michel Zwaan Fr édéric Millot Briana Patterson Jill Sami Source Type: research
Effervescent tablet-assisted deep eutectic solvent based on magnetic nanofluid for liquid phase microextraction of tyrosine kinase inhibitors in plasma samples by high-performance liquid chromatography
CONCLUSIONS: The developed method displayed high sensitivity, low consumption of solvent, low cost, simplicity, high recoveries, short extraction time, and good repeatability for determination of three anti-cancer drugs in human plasma samples.PMID:37717246 | DOI:10.1007/s43440-023-00524-x (Source: Pharmacological Reports)
Source: Pharmacological Reports - September 17, 2023 Category: Drugs & Pharmacology Authors: Khosrou Abdi Maryam Ezoddin Laleh Adlnasab Bahar Aziz Kabiri Mohammad Ali Karimi Somaye Behnamipour Houman Alimoradi Source Type: research
Effervescent tablet-assisted deep eutectic solvent based on magnetic nanofluid for liquid phase microextraction of tyrosine kinase inhibitors in plasma samples by high-performance liquid chromatography
CONCLUSIONS: The developed method displayed high sensitivity, low consumption of solvent, low cost, simplicity, high recoveries, short extraction time, and good repeatability for determination of three anti-cancer drugs in human plasma samples.PMID:37717246 | DOI:10.1007/s43440-023-00524-x (Source: Pharmacological Reports)
Source: Pharmacological Reports - September 17, 2023 Category: Drugs & Pharmacology Authors: Khosrou Abdi Maryam Ezoddin Laleh Adlnasab Bahar Aziz Kabiri Mohammad Ali Karimi Somaye Behnamipour Houman Alimoradi Source Type: research
Novel design of dual-action Pt(IV) anticancer pro-drugs based on cisplatin and derivatives of the Tyrosine Kinase Inhibitors imatinib and nilotinib
This article is licensed under aCreative Commons Attribution 3.0 Unported Licence.Darren Fergal Beirne, Barbara Farkas, Chiara Donati, Valentina Gandin, Isabel Rozas, Trinidad Velasco-Torrijos, Diego Montagner Tyrosine Kinases (TKs) are emerging as important targets in cancer therapy and some of their inhibitors TKi (i.e. Imatinib and Nilotinib) are FDA approved drugs that are used as selective... The content of this RSS Feed (c) The Royal Society of Chemistry (Source: RSC - Dalton Trans. latest articles)
Source: RSC - Dalton Trans. latest articles - September 7, 2023 Category: Chemistry Authors: Darren Fergal Beirne Source Type: research
ZAK α/P38 kinase signaling pathway regulates hematopoiesis by activating the NLRP1 inflammasome
In conclusion, our results reveal that the NLRP1 inflammasome regulates hematopoiesis and pave the way to develop novel therapeutic strategies for the treatment of hematopoietic alterations associated with chronic inflammatory and rare diseases.PMID:37675820 | DOI:10.15252/emmm.202318142 (Source: Molecular Medicine)
Source: Molecular Medicine - September 7, 2023 Category: Molecular Biology Authors: Lola Rodr íguez-Ruiz Juan M Lozano-Gil Elena Naranjo-S ánchez Elena Mart ínez-Balsalobre Alicia Mart ínez-López Christophe Lachaud Miguel Blanquer Toan K Phung Diana Garc ía-Moreno Mar ía L Cayuela Sylwia D Tyrkalska Ana B P érez-Oliva Victoriano Source Type: research
Nilotinib alleviates paraquat-induced hepatic and pulmonary injury in rats via the Nrf2/Nf-kB axis
Int Immunopharmacol. 2023 Sep 5;124(Pt A):110886. doi: 10.1016/j.intimp.2023.110886. Online ahead of print.ABSTRACTBACKGROUND: Paraquat (PQ, 1,1'-dimethyl-4-4'-bipyridinium dichloride) is a highly toxic quaternary ammonium herbicide widely used in agriculture. It exerts its toxic effects mainly as a result of its redox cycle via the production of superoxide anions in organisms, leading to an imbalance in the redox state of the cell causing oxidative damage and finally cell death. The aim of this study was to estimate the beneficial protective role of nilotinib (NIL) on PQ-induced hepatic and pulmonary toxicity in rats.METH...
Source: International Immunopharmacology - September 7, 2023 Category: Allergy & Immunology Authors: Azza R Elkholy Ahmed R El-Sheakh Ghada M Suddek Source Type: research
Nilotinib alleviates paraquat-induced hepatic and pulmonary injury in rats via the Nrf2/Nf-kB axis
Int Immunopharmacol. 2023 Sep 5;124(Pt A):110886. doi: 10.1016/j.intimp.2023.110886. Online ahead of print.ABSTRACTBACKGROUND: Paraquat (PQ, 1,1'-dimethyl-4-4'-bipyridinium dichloride) is a highly toxic quaternary ammonium herbicide widely used in agriculture. It exerts its toxic effects mainly as a result of its redox cycle via the production of superoxide anions in organisms, leading to an imbalance in the redox state of the cell causing oxidative damage and finally cell death. The aim of this study was to estimate the beneficial protective role of nilotinib (NIL) on PQ-induced hepatic and pulmonary toxicity in rats.METH...
Source: International Immunopharmacology - September 7, 2023 Category: Allergy & Immunology Authors: Azza R Elkholy Ahmed R El-Sheakh Ghada M Suddek Source Type: research
Cancers, Vol. 15, Pages 4354: Hematological Adverse Events with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review with Meta-Analysis
In conclusion, the overall prevalence of hematological AEs by TKI type was: dasatinib > bosutinib > imatinib > nilotinib. Study limitations include inability to normalize for dosage and treatment duration. (Source: Cancers)
Source: Cancers - August 31, 2023 Category: Cancer & Oncology Authors: Olivia Kronick Xinyu Chen Nidhi Mehra Armon Varmeziar Rachel Fisher David Kartchner Vamsi Kota Cassie S. Mitchell Tags: Systematic Review Source Type: research
IL-33-ST2 signaling promotes stemness in subtypes of myeloid leukemia cells through the Wnt and Notch pathways
Sci Signal. 2023 Aug 29;16(800):eadd7705. doi: 10.1126/scisignal.add7705. Epub 2023 Aug 29.ABSTRACTCell stemness is characterized by quiescence, pluripotency, and long-term self-renewal capacity. Therapy-resistant leukemic stem cells (LSCs) are the primary cause of relapse in patients with chronic and acute myeloid leukemia (CML and AML). However, the same signaling pathways frequently support stemness in both LSCs and normal hematopoietic stem cells (HSCs), making LSCs difficult to therapeutically target. In cell lines and patient samples, we found that interleukin-33 (IL-33) signaling promoted stemness only in leukemia c...
Source: Science Signaling - August 29, 2023 Category: Biomedical Science Authors: Pascal Naef Ramin Radpour Carla A Jaeger-Ruckstuhl Nils Bodmer Gabriela M Baerlocher Hartmut Doehner Konstanze Doehner Carsten Riether Adrian F Ochsenbein Source Type: research
IL-33-ST2 signaling promotes stemness in subtypes of myeloid leukemia cells through the Wnt and Notch pathways
Sci Signal. 2023 Aug 29;16(800):eadd7705. doi: 10.1126/scisignal.add7705. Epub 2023 Aug 29.ABSTRACTCell stemness is characterized by quiescence, pluripotency, and long-term self-renewal capacity. Therapy-resistant leukemic stem cells (LSCs) are the primary cause of relapse in patients with chronic and acute myeloid leukemia (CML and AML). However, the same signaling pathways frequently support stemness in both LSCs and normal hematopoietic stem cells (HSCs), making LSCs difficult to therapeutically target. In cell lines and patient samples, we found that interleukin-33 (IL-33) signaling promoted stemness only in leukemia c...
Source: Science Signaling - August 29, 2023 Category: Biomedical Science Authors: Pascal Naef Ramin Radpour Carla A Jaeger-Ruckstuhl Nils Bodmer Gabriela M Baerlocher Hartmut Doehner Konstanze Doehner Carsten Riether Adrian F Ochsenbein Source Type: research
